Antiallergic composition

An anti-allergic and composition technology, applied in the application field, can solve the problems such as the inability to explain the degree of IgE

Inactive Publication Date: 2006-05-03
KIRIN HOLDINGS KK
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The traditional method is to evaluate the anti-allergic activity by measuring IgE. Although the relationship between IgE and allergy is unquestionable, on the other hand, for example, it is known that there are people with high IgE and low IgE among atopic patients. , the degree of IgE does not tell everything

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antiallergic composition
  • Antiallergic composition
  • Antiallergic composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] (The lactic acid bacteria used in the embodiment of the present invention)

[0073] The lactic acid bacteria used in the examples of the present invention and the results obtained are shown in Figure 1 (No.1) and Figure 2 (No.2). All bacterial strains in the present invention are identified by sequence numbers beginning with KW. Some of these test strains were isolated independently, some were used in commercial dairy products, and some were obtained from public institutions. For convenience, their identification names were unified. The relationship between each KW strain and its source is shown in Figure 1 (No.1) and Figure 2 (No.2). In the "acquisition place" in Fig. 1, "JCM" stands for Japan Collection of Microorganisms, and "IFO" stands for the former Institute of Fermentation (currently the Bioresource Center (NBRC), an independent administrative institution for product evaluation technology).

Embodiment 2

[0075] (Evaluation of antiallergic activity of lactic acid bacteria in vitro)

[0076] 1. Sample

[0077] (de Man, Rogosa, Sharpe) culture medium (OXOID) each strain of lactic acid bacteria was cultivated for 48 hours, washed 3 times with sterilized water, suspended in sterilized water, treated at 100°C for 30 minutes, and sterilized. It was lyophilized and suspended in PBS. For the lactic acid bacteria used, refer to Fig. 1 (No. 1) and Fig. 2 (No. 2).

[0078] 2. Experimental animals, breeding

[0079] On day 0 and day 6, 7-10 week old BALB / c mice (Charles River) were intraperitoneally injected with 1 mg of ovalbumin (OVA) and 2 mg of adjuvant Alum. On the 13th day, the spleen was dissected, and the lymphocytes were prepared. In the experiment, n=6.

[0080] 3. Determination of IL-4 and IL-12 in splenocytes

[0081] IL-4 and IL-12 were measured with OptEIA ELISA Set (Becton Dickinson).

[0082] 4. Experimental conditions

[0083] Use RPMI1640 (SIGMA)+10%FCS (Rosche)+1...

Embodiment 3

[0092] (Selection of Derivatives)

[0093] This example is an example of selecting a strain with anti-allergic activity from the strains derived from the lactic acid bacteria strain KW3110 obtained in the present invention. Culture KW3110 strain statically in MRS medium at 37°C until its OD600 value is 0.8-1.0.

[0094] After diluting the culture solution with fresh MRS medium to OD600 = 0.5, suspend the bacterial cell suspension at a ratio of 10% in PBS adjusted to pH 3.0 with hydrochloric acid (dissolve tablets made by Dainippoin Pharmaceutical at the specified concentration) Incubate at 37°C for 3 hours. Dilute the acid-treated bacterial suspension with PBS and transfer it to MRS plate medium to form colonies. Pale colonies can be seen among the colonies formed. The colonies were selected and cultured in MRS medium for 48 hours. The strain was named No.90 strain. Measure the antiallergic activity of No.90 strain with the method of embodiment 2. Compared with the wild ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An object of the present invention is to provide an antiallergic composition useful for preventing and treating allergies, its preparation method, and its use as food, beverages, and the like. The solution includes an anti-allergic composition, which contains lactic acid bacteria with the following effects as an active ingredient: lymphocytes derived from the spleen of mice sensitized with ovalbumin are suspended in a culture medium containing ovalbumin, and added to When the lactic acid bacteria to be tested are cultured, the production of interleukin 12 is equivalent to that when Lactobacillus casei-like KW3110 strain is used as the lactic acid bacteria to be tested, or more than 60% of that when Lactobacillus casei-like KW3110 strain is used as the lactic acid bacteria to be tested, and the interleukin 12 The production amount of 4 was less than 50% of the control without adding lactic acid bacteria. The present invention includes a method for obtaining lactic acid bacteria with high anti-allergic activity as an active ingredient of the anti-allergic composition of the present invention, and the application of the anti-allergic composition of the present invention in food, beverages, etc., and further includes a method for preparing the lactic acid bacteria with high anti-allergic activity. , for use as an orally administered antiallergic agent.

Description

technical field [0001] The present invention relates to an antiallergic composition useful for the prevention and treatment of allergic reactions, especially an antiallergic composition containing lactic acid bacteria with high antiallergic activity as an active ingredient, and a method for obtaining the lactic acid bacteria, and also relates to the antiallergic Use the composition for applications such as food and beverages. technical background [0002] Allergy is one of the most prevalent diseases in developed countries. The pathogenesis of allergies is usually divided into 4 types from type I to type IV. Type I allergy is related to IgE antibody, represented by hay fever, asthma, urticaria, and anaphylactic shock. Type II allergy is related to IgG antibody and IgM antibody, and is a cytotoxic reaction caused by activation of the complement system. Fetal myeloerythroblastosis and autoimmune hemolytic anemia belong to this type. Type III allergy is a tissue injury react...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A23L2/52A61K35/74A23C9/123A23F3/16A23F3/34A23F5/24A23L1/28A23L1/30A23L2/02A23L2/68A23L31/00A23L33/135A61K35/747A61P11/02A61P11/06A61P17/00A61P27/02A61P27/14A61P27/16A61P31/00A61P35/00A61P37/08A61P43/00C12N1/20C12Q1/02C12R1/225
CPCA23C9/1234A23F3/166A23F3/34A23F5/246A23L2/52A61K35/747A23L33/135A61P11/02A61P11/06A61P17/00A61P17/04A61P27/02A61P27/14A61P27/16A61P31/00A61P35/00A61P37/08A61P43/00A23V2400/169A61K35/74
Inventor 井上小夜藤井敏雄藤原大介斋木朗高桥实山内浩一郎后藤正巳西田聪出内桂二若林英行米田俊浩
Owner KIRIN HOLDINGS KK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap